Poison of intestinal induce severe health problems in human infants and young animals due to contaminating foods and feedstuffs. With the emergence of public health concerns and high-speed diffuse of
drug-opposition of bacteria, the adoption of
antimicrobial peptides as potential candidates in treating pathogen
infections raised up. Nature
Microcin J25 (
MccJ25), a class of lasso
peptides separated from a fecal strain of E. coli, has been replied to display powerful antimicrobial behavior. Herein, the study was to assess the usefulness of biogenic
MccJ25 in the prophylaxis of ETEC K88
infection in IPEC-J2 cells. In vitro antimicrobial activity against ETEC K88 and cytotoxicity of biogenic
MccJ25 were determined first. To further understand how biogenic
MccJ25 mediates its impact, ETEC K88 adhesion in cells, membrane permeability [as indicated by reduced release of
lactate dehydrogenase (LDH)], transepithelial electrical resistance (TEER), barrier function, and proinflammatory
cytokines levels were determined in IPEC-J2 cells
after treatment with biogenic
MccJ25 and challenge with ETEC K88. Biogenic
MccJ25 had a minimum inhibitory concentration of 0.25 μg/mL against ETEC K88, decreased ETEC K88 adhesion in cells and did not cause cytotoxicity toward cells. Furthermore, biogenic
MccJ25 protects against ETEC-induced barrier dysfunction by increasing the TEER, decreasing the LDH and promoting
tight junction proteins (TJPs) by promoting the assembly of
occludin and
claudin-1 in the tight junction complex. Biogenic
MccJ25 was further found to relieve
inflammation responses through modulation of interleukine-6,
IL-8 and
tumor necrosis factor-α levels via inhibition of
mitogen-activated protein kinase (MAPK) and nuclear factor κB activation. In summary, biogenic
MccJ25 can protects against ETEC K88-induced intestinal damage and inflammatory response, recommend the hidden adoption of biogenic
MccJ25 as a novel prophylactic agent to reduce pathogen
infection in animals, food or humans.